Table 5.

Median peripheral blood immune cell counts and indexes at 4 and 6 weeks after ICI initiation according to the early use of steroids

	4 weeks					6 weeks
	Control cohort		Exposed cohort		P value*	Control cohort		Exposed cohort		P value*
	Median	IQR	Median	IQR		Median	IQR	Median	IQR
WBC†	7.52	6.22–8.94	8.76	8.08–12.20	<0.001	7.75	6.19–9.73	8.67	7.35–11.22	0.01
ANC†	5.00	3.80–6.20	7.00	5.60–9.70	<0.001	5.15	3.70–6.90	7.45	5.78–8.73	<0.001
ALC†	1.50	1.00–1.90	1.10	0.80–1.70	0.07	1.50	1.10–1.90	1.0	0.70–1.70	0.004
AMC†	0.50	0.40–0.60	0.60	0.50–0.60	0.08	0.50	0.40–0.60	0.50	0.40–0.70	0.82
AEC†	0.20	0.10–0.30	0.10	0.10–0.20	0.009	0.20	0.10–0.30	0.10	0.00–0.20	<0.001
REC‡	2.60	1.50–3.80	1.20	0.70–3.30	<0.001	2.35	1.30–3.90	1.20	0.00–2.40	<0.001
ABC†	0.00	0.00–0.10	0.00	0.00–0.00	0.46	0.00	0.00–0.10	0.00	0.00–0.10	0.61
NLR	3.4	2.4–5.2	6.9	3.5–10.6	<0.001	3.6	2.4–5.4	8.1	3.2–14.6	<0.001
dNLR	2.0	1.6–2.8	3.6	2.6–4.9	<0.001	2.2	1.6–3.0	4.0	2.3–5.8	<0.001

P values below the significance threshold are reported in bold.

*Wilcoxon test.

†×10³.

‡%.

ABC, absolute basophil count; AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; dNLR, derived neutrophil to lymphocyte ratio.ICI, immune checkpoint inhibitor; NLR, neutrophil to lymphocyte ratio; REC, relative eosinophil count; WBC, white blood count;